Rani Therapeutics Holdings (RANI) has released an update.
Rani has revealed promising topline results from their RT-111 Phase 1 clinical trial, showing its orally administered ustekinumab biosimilar capsule to be well-tolerated with no serious adverse events. The trial, involving 55 healthy volunteers, demonstrated high bioavailability when compared to the conventional subcutaneous injection, with no significant difference in the development of anti-drug antibodies. This breakthrough suggests a potential new oral delivery method for the drug, offering a more convenient option for patients.
For further insights into RANI stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
